Skip to search formSkip to main contentSkip to account menu

sotagliflozin

Known as: Beta-l-Xylopyranoside, methyl 5-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-1-thio-, (5S)- 
An orally bioavailable inhibitor of the sodium-glucose co-transporter subtype 1 (SGLT1) and 2 (SGLT2), with potential antihyperglycemic activity… 
National Institutes of Health

Related topics

Related topics

1 relation

Narrower (1)

LX4211

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2020
Review
2020
Using real‐world safety data in regulatory approval decisions: Sotagliflozin and the risk of diabetic ketoacidosis
In 2016, the 21st Century Cures Act directed the Food and Drug Administration (FDA) to evaluate the potential use of real-world… 
2019
2019
A comparison of sotagliflozin therapy for diabetes mellitus between week 24 with week 52
Abstract Background: According to the centers for disease control and prevention, 14% of American adults have diabetes – 10% know… 
2019
2019
OR22-5 Sotagliflozin Decreases Postprandial Glucose and Insulin by Delaying Intestinal Glucose Absorption
Abstract Sotagliflozin (Sota) inhibits sodium glucose cotransporter 2 (SGLT2; IC50=1.8 nM) and SGLT1 (IC50=36 nM). In humans… 
Review
2018
Review
2018
Efficacy and safety of sotagliflozin in treating diabetes type 1
ABSTRACT Introduction: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. Sotagliflozin blocks… 
2018
2018
Effects of Sotagliflozin Added to Insulin in Type 1 Diabetes.
2018
2018
Does a gluten-free diet determine the efficacy of sotagliflozin in patients with concomitant type 1 diabetes mellitus and celiac disease?
Sodium glucose-cotransporter type 2 (SGLT-2) inhibitors constitute a novel class of antidiabetics, approved for the treatment of… 
Review
2018
Review
2018
Review: In adults with type 1 diabetes, SGLT-2 inhibitors reduce HbA1c but increase diabetic ketoacidosis
Question In adults with type 1 diabetes, what are the efficacy and safety of adding sodiumglucose cotransporter 2 (SGLT-2… 
2017
2017
Genomics pioneer gets its first drug
2015
2015
Sotagliflozin improves glycemic control in nonobese diabetes-prone mice with type 1 diabetes
Purpose Oral agents are needed that improve glycemic control without increasing hypoglycemic events in patients with type 1… 
2014
2014
SGLT-1/SGLT-2 Inhibitor Shows Promise in Patients with T2DM, Renal Impairment
The investigational LX4211 may one day fill a need for these patients who are unable to eliminate a lot of glucose in urine and… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)